A Phase 1/2 interventional study of ATSN-101 and ATSN-101 Diluent Solution in Leber Congenital Amaurosis, LCA and LCA1, sponsored by Atsena Therapeutics Inc.. Active, not recruiting at 2 sites in United States. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2026-08-03.
Sponsored by Atsena Therapeutics Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Leber Congenital Amaurosis with a site in United States — 4 open to participants now, 9 under way, 3 of them phase 3. Leber Congenital Amaurosis · United States.
Among the 23 studies in Leber Congenital Amaurosis with a site in United States, this one is the 9th largest by enrollment of the 16 interventional ones that give a count, is one of 5 that started in 2019, is one of 9 in phase 1/2, and was the 19th registered.
32 studies on the registry are indexed under Leber Congenital Amaurosis; 4 are open to participants now.
Browse Leber Congenital Amaurosis studies →4 of the 23 studies in Leber Congenital Amaurosis with a site in United States are open now. Recruiting first, the newest first:
Opus Genetics, Inc · Sites in United States
Ages 18+
Laboratoires Thea · Sites in United States, Australia, Belgium and 7 more countries
Ages 6+
Foundation Fighting Blindness · Sites in United States
Healthy volunteers
Sanford Health · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 4 Leber Congenital Amaurosis studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.
This study: 6 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 10 · Phase 3 3
First in 2007; this study’s year is marked. 5 started in 2019.
This study's enrollment of 15 is close to the median of 15 across 23 interventional studies indexed under Leber Congenital Amaurosis.
Median enrollment 18 across the 16 interventional studies, 59 across the 7 observational. Of the 12 that completed or were terminated, 3 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 23 have an industry lead sponsor. The 10 most frequent:
Atsena Therapeutics Inc. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Atsena Therapeutics Inc. has 1 study filed under Leber Congenital Amaurosis — fewer than ten, so there is no comparison to draw.
3 of the studies in Leber Congenital Amaurosis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06891443Phase 3Laboratoires TheaStudy to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION) | 2027-11 |
| NCT05203939OcugenStudy to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis | 2027-03 |
| NCT01208389Spark Therapeutics, Inc.Phase 1 Follow-on Study of AAV2-hRPE65v2 Vector in Subjects With Leber Congenital Amaurosis (LCA) 2 | 2027-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies in Leber Congenital Amaurosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To evaluate the safety and tolerability of ascending doses of ATSN-101 administered as a unilateral subretinal injection in patients with Leber Congenital Amaurosis (LCA) caused by autosomal recessive guanylate cyclase 2D (GUCY2D) mutations (GUCY2D-LCA).
Secondary Objective:
To evaluate the efficacy of ascending doses of ATSN-101 administered as a unilateral subretinal injection in patients with GUCY2D-LCA.
Study duration per participant is approximately 112 weeks including: an approximately 56-day screening/baseline period, an approximately 52-week study observation period including 1 treatment day, and an approximately 52-week safety follow-up period. The end of study visit will be approximately 260 weeks after the Investigational Medicinal Product (IMP) administration.
The study is separated into 2 parts including a dose escalation phase (Part A) and a dose expansion phase (Part B). In Part B participants will be treated at the maximum tolerated dose (MTD) or maximum administered dose (MAD) determined from Part A.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ATSN-101 single dose according to an ascending dose design (dose escalation phase) or ATSN-101 single dose (dose expansion phase)
Drug: ATSN-101 · Drug: ATSN-101 Diluent Solution · Drug: Prednisone · Drug: Triamcinalone Acetonide · Drug: 1% Prednisolone · Drug: Trimethoprim/polymyxin B
Pharmaceutical form:Solution for intraocular administration Route of administration: Subretinal injection
Pharmaceutical form:Solution for parenteral use Route of administration: Subretinal injection
Pharmaceutical form:Tablet Route of administration: Oral
Pharmaceutical form:Suspension Route of administration: Peri-ocular injection
Pharmaceutical form:Suspension Route of administration: Drops
Drug pages: TrimethoprimStudies of TrimethoprimTrimethoprim pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Polymyxin BStudies of Polymyxin BPolymyxin B pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Pharmaceutical form:Solution Route of administration: Topical
Number of Participants With Adverse Events (AEs) From Baseline up to the End of the Observation Period
Number of participants with treatment-emergent AEs will be summarized in each cohort (this includes cohorts 1 - 5)
Time frame: From Baseline to Week 52
Change From Baseline of Best-Corrected Visual Acuity (BCVA) Between the Treated and Untreated Eyes
Mean change from Baseline to Week 52 in BCVA (LogMAR) in the treated eye and untreated eye (control). In logMAR notation (logarithm of the minimum angle of resolution) is interpreted as follows: Lower LogMAR values indicates better vision. Higher LogMAR values indicates worse vision.
Time frame: Baseline to Week 52
Change From Baseline of Sensitivity Between the Treated and Untreated Eye - Light Adapted
Mean change from Baseline to Week 52 in sensitivity as measured by the full-field stimulus testing - Light Adapted in the treated eye and untreated eye. Full-field stimulus testing was performed for three stimulus colors - blue, red, and white.
Time frame: Baseline to Week 52
Mean Change From Baseline of Sensitivity Between the Treated and Untreated Eye - Dark Adapted
Mean change from Baseline to Week 52 in sensitivity as measured by the full-field stimulus testing - Dark Adapted in the treated eye and untreated eye. Full-field stimulus testing was performed for three stimulus colors - blue, red, and white.
Time frame: Baseline to Week 52
Number of Participants With Adverse Events (AEs) From Baseline up to the End of the Observation Period
Number of participants with treatment-emergent AEs will be summarized in each cohort (this includes cohorts 1 - 5)
Time frame: From Baseline to Week 260
Change From Baseline of Best-Corrected Visual Acuity (BCVA) Between the Treated and Untreated Eyes
Mean change from Baseline to Week 260 in BCVA (LogMAR) in the treated eye and untreated eye (control). In logMAR notation (logarithm of the minimum angle of resolution) is interpreted as follows: Lower LogMAR values indicates better vision. Higher LogMAR values indicates worse vision.
Time frame: Baseline to Week 260
Change From Baseline of Sensitivity Between the Treated and Untreated Eye - Light Adapted
Mean change from Baseline to Week 260 in sensitivity as measured by the full-field stimulus testing - Light Adapted in the treated eye and untreated eye. Full-field stimulus testing was performed for three stimulus colors - blue, red, and white.
Time frame: Baseline to Week 260
Mean Change From Baseline of Sensitivity Between the Treated and Untreated Eye - Dark Adapted
Mean change from Baseline to Week 260 in sensitivity as measured by the full-field stimulus testing - Dark Adapted in the treated eye and untreated eye. Full-field stimulus testing was performed for three stimulus colors - blue, red, and white.
Time frame: Baseline to Week 260
Study screening and enrollment occurred between October 2019 through May 2022. A total of 23 patients were screened, resulting in 2 enrollments at the Casey Eye Institute - Oregon Health and Science University and 13 enrollments at the Scheie Eye Institute - University of Pennsylvania to reach the study's goal of 15 enrolled patients across all cohorts.
| Milestone | ATSN-101 Cohort 1 | ATSN-101 Cohort 2 | ATSN-101 Cohort 3 | ATSN-101 Cohort 4 (Adult Expansion) | ATSN-101 Cohort 5 (Pediatric Expansion) |
|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 3 | 3 |
| Completed | 3 | 3 | 3 | 3 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| Milestone | ATSN-101 Cohort 1 | ATSN-101 Cohort 2 | ATSN-101 Cohort 3 | ATSN-101 Cohort 4 (Adult Expansion) | ATSN-101 Cohort 5 (Pediatric Expansion) |
|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 3 | 3 |
| Completed | 0 | 0 | 0 | 0 | 0 |
| Not completed | 3 | 3 | 3 | 3 | 3 |
Number of participants with treatment-emergent AEs will be summarized in each cohort (this includes cohorts 1 - 5)
| Participants | ATSN-101 Cohort 1 | ATSN-101 Cohort 2 | ATSN-101 Cohort 3 | ATSN-101 Cohort 4 (Adult Expansion) | ATSN-101 Cohort 5 (Pediatric Expansion) |
|---|---|---|---|---|---|
| Number of Participants With Adverse Events (AEs) From Baseline up to the End of the Observation Period | 3 | 3 | 3 | 3 | 3 |
Mean change from Baseline to Week 52 in BCVA (LogMAR) in the treated eye and untreated eye (control). In logMAR notation (logarithm of the minimum angle of resolution) is interpreted as follows: Lower LogMAR values indicates better vision. Higher LogMAR values indicates worse vision.
| LogMAR | Treated Eye | Untreated Eye |
|---|---|---|
| ATSN-101 Cohort 1 | -0.27 ± 0.30 | -0.19 ± 0.35 |
| ATSN-101 Cohort 2 | -0.08 ± 0.09 | -0.04 ± 0.04 |
| ATSN-101 Cohort 3 | -0.37 ± 0.47 | 0.00 ± 0.00 |
| ATSN-101 Cohort 4 (Adult Expansion) | -0.12 ± 0.11 | 0.03 ± 0.03 |
| ATSN-101 Cohort 5 (Pediatric Expansion) | -0.05 ± 0.18 | -0.01 ± 0.02 |
| ATSN-101 High Dose | -0.16 ± 0.25 | 0.01 ± 0.03 |
Mean change from Baseline to Week 52 in sensitivity as measured by the full-field stimulus testing - Light Adapted in the treated eye and untreated eye. Full-field stimulus testing was performed for three stimulus colors - blue, red, and white.
| dB | Treated Eye | Untreated Eye |
|---|---|---|
| ATSN-101 Cohort 1 - Blue | 0.81 ± 3.09 | -1.11 ± 3.10 |
| ATSN-101 Cohort 2 - Blue | 1.44 ± 3.10 | 3.14 ± 4.21 |
| ATSN-101 Cohort 3 - Blue | 1.00 ± 0.94 | 4.83 ± 2.12 |
| ATSN-101 Cohort 4 (Adult Expansion) - Blue | -0.87 ± 6.09 | -1.51 ± 3.74 |
| ATSN-101 Cohort 5 (Pediatric Expansion) - Blue | 5.53 ± 14.29 | 6.92 ± 10.31 |
| ATSN-101 High Dose - Blue | 2.00 ± 8.84 | 3.24 ± 7.15 |
| ATSN-101 Cohort 1 - Red | 2.06 ± 2.71 | 0.78 ± 2.04 |
| ATSN-101 Cohort 2 - Red | 3.12 ± 5.72 | 1.71 ± 2.89 |
| ATSN-101 Cohort 3 - Red | 14.20 ± 1.90 | 6.67 ± 5.66 |
| ATSN-101 Cohort 4 (Adult Expansion) - Red | 2.67 ± 2.36 | -0.17 ± 4.01 |
| ATSN-101 Cohort 5 (Pediatric Expansion) - Red | -3.67 ± 0.47 | 0.17 ± 2.59 |
| ATSN-101 High Dose - Red | 4.40 ± 8.22 | 2.22 ± 4.78 |
| ATSN-101 Cohort 1 - White | 1.13 ± 2.80 | 1.67 ± 3.33 |
| ATSN-101 Cohort 2 - White | 1.70 ± 2.52 | 0.90 ± 3.73 |
| ATSN-101 Cohort 3 - White | 2.50 ± 1.41 | 3.00 ± 3.54 |
| ATSN-101 Cohort 4 (Adult Expansion) - White | 3.10 ± 4.00 | 0.32 ± 1.74 |
| ATSN-101 Cohort 5 (Pediatric Expansion) - White | 4.60 ± 13.87 | -2.00 ± 4.24 |
| ATSN-101 High Dose - White | 3.51 ± 7.79 | 0.42 ± 3.20 |
Mean change from Baseline to Week 52 in sensitivity as measured by the full-field stimulus testing - Dark Adapted in the treated eye and untreated eye. Full-field stimulus testing was performed for three stimulus colors - blue, red, and white.
| dB | Treated Eye | Untreated Eye |
|---|---|---|
| ATSN-101 Cohort 1 - Blue | 6.89 ± 6.19 | 2.78 ± 3.91 |
| ATSN-101 Cohort 2 - Blue | 2.11 ± 3.34 | -0.78 ± 3.10 |
| ATSN-101 Cohort 3 - Blue | 29.92 ± 11.67 | -2.49 ± 1.63 |
| ATSN-101 Cohort 4 (Adult Expansion) - Blue | 25.53 ± 21.88 | 1.60 ± 6.57 |
| ATSN-101 Cohort 5 (Pediatric Expansion) - Blue | 6.54 ± 5.95 | 2.59 ± 6.27 |
| ATSN-101 High Dose - Blue | 21.36 ± 17.16 | 0.95 ± 5.35 |
| ATSN-101 Cohort 1 - Red | 6.22 ± 6.05 | 1.33 ± 1.76 |
| ATSN-101 Cohort 2 - Red | 3.33 ± 9.43 | -4.00 ± 3.77 |
| ATSN-101 Cohort 3 - Red | 28.67 ± 14.61 | 0.17 ± 4.01 |
| ATSN-101 Cohort 4 (Adult Expansion) - Red | 18.49 ± 11.16 | 2.89 ± 4.73 |
| ATSN-101 Cohort 5 (Pediatric Expansion) - Red | 12.18 ± 10.97 | -3.69 ± 15.73 |
| ATSN-101 High Dose - Red | 18.67 ± 12.13 | -0.26 ± 9.42 |
| ATSN-101 Cohort 1 - White | 5.37 ± 7.16 | 1.22 ± 2.91 |
| ATSN-101 Cohort 2 - White | 0.89 ± 5.50 | -0.78 ± 7.30 |
| ATSN-101 Cohort 3 - White | 28.50 ± 21.21 | -2.00 ± 4.95 |
| ATSN-101 Cohort 4 (Adult Expansion) - White | 24.94 ± 20.18 | 1.04 ± 5.13 |
| ATSN-101 Cohort 5 (Pediatric Expansion) - White | 7.17 ± 6.60 | 4.20 ± 6.65 |
| ATSN-101 High Dose - White | 20.88 ± 17.56 | 1.08 ± 5.16 |
Number of participants with treatment-emergent AEs will be summarized in each cohort (this includes cohorts 1 - 5)
Results for this outcome have not been posted.
Mean change from Baseline to Week 260 in BCVA (LogMAR) in the treated eye and untreated eye (control). In logMAR notation (logarithm of the minimum angle of resolution) is interpreted as follows: Lower LogMAR values indicates better vision. Higher LogMAR values indicates worse vision.
Results for this outcome have not been posted.
Mean change from Baseline to Week 260 in sensitivity as measured by the full-field stimulus testing - Light Adapted in the treated eye and untreated eye. Full-field stimulus testing was performed for three stimulus colors - blue, red, and white.
Results for this outcome have not been posted.
Mean change from Baseline to Week 260 in sensitivity as measured by the full-field stimulus testing - Dark Adapted in the treated eye and untreated eye. Full-field stimulus testing was performed for three stimulus colors - blue, red, and white.
Results for this outcome have not been posted.
Collected over From Baseline through Week 52. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ATSN-101 Cohort 1 | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| ATSN-101 Cohort 2 | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| ATSN-101 Cohort 3 | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| ATSN-101 Cohort 4 (Adult Expansion) | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| ATSN-101 Cohort 5 (Pediatric Expansion) | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Event | ATSN-101 Cohort 1 | ATSN-101 Cohort 2 | ATSN-101 Cohort 3 | ATSN-101 Cohort 4 (Adult Expansion) | ATSN-101 Cohort 5 (Pediatric Expansion) |
|---|---|---|---|---|---|
| Macular HoleEye disorders | 0/3 | 1/3 | 0/3 | 0/3 | 0/3 |
| EndopthalmitisInfections and infestations | 0/3 | 0/3 | 0/3 | 0/3 | 1/3 |
| Retinal DetachmentEye disorders | 0/3 | 0/3 | 0/3 | 0/3 | 1/3 |
| Event | ATSN-101 Cohort 1 | ATSN-101 Cohort 2 | ATSN-101 Cohort 3 | ATSN-101 Cohort 4 (Adult Expansion) | ATSN-101 Cohort 5 (Pediatric Expansion) |
|---|---|---|---|---|---|
| Conjunctival HaemorrhageEye disorders | 3/3 | 3/3 | 2/3 | 2/3 | 3/3 |
| Ocular DiscomfortEye disorders | 3/3 | 3/3 | 2/3 | 2/3 | 2/3 |
| Hypotony Of EyeEye disorders | 2/3 | 2/3 | 1/3 | 2/3 | 1/3 |
| Retinal TearEye disorders | 1/3 | 0/3 | 0/3 | 0/3 | 0/3 |
| Vitreal CellsEye disorders | 1/3 | 0/3 | 0/3 | 1/3 | 1/3 |
| Ocular HypertensionEye disorders | 1/3 | 0/3 | 0/3 | 0/3 | 0/3 |
| NasopharyngitisInfections and infestations | 0/3 | 1/3 | 1/3 | 1/3 | 1/3 |
| Eye InflammationEye disorders | 0/3 | 0/3 | 1/3 | 1/3 | 0/3 |
| Eye PainEye disorders | 0/3 | 0/3 | 1/3 | 0/3 | 1/3 |
| Conjunctival HyperaemiaEye disorders | 0/3 | 0/3 | 1/3 | 1/3 | 1/3 |
The baseline for a given parameter is defined as the last assessment for this parameter before first administration of the investigational medicinal product (IMP).
| Age, Continuous(Years) | ATSN-101 Cohort 1 | ATSN-101 Cohort 2 | ATSN-101 Cohort 3 | ATSN-101 Cohort 4 (Adult Expansion) | ATSN-101 Cohort 5 (Pediatric Expansion) | Total |
|---|---|---|---|---|---|---|
| Mean | 33.7 ± 11.06 | 23.3 ± 7.57 | 23.7 ± 7.37 | 39.0 ± 32.08 | 14.0 ± 1.73 | 26.7 ± 16.21 |
| Sex: Female, Male(Participants) | ATSN-101 Cohort 1 | ATSN-101 Cohort 2 | ATSN-101 Cohort 3 | ATSN-101 Cohort 4 (Adult Expansion) | ATSN-101 Cohort 5 (Pediatric Expansion) | Total |
|---|---|---|---|---|---|---|
| Female | 2 | 1 | 3 | 2 | 2 | 10 |
| Male | 1 | 2 | 0 | 1 | 1 | 5 |
| Race/Ethnicity, Customized(Participants) | ATSN-101 Cohort 1 | ATSN-101 Cohort 2 | ATSN-101 Cohort 3 | ATSN-101 Cohort 4 (Adult Expansion) | ATSN-101 Cohort 5 (Pediatric Expansion) | Total |
|---|---|---|---|---|---|---|
| Race — American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Race — Asian | 1 | 0 | 1 | 1 | 0 | 3 |
| Race — Black or African American | 0 | 0 | 0 | 0 | 0 | 0 |
| Race — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Race — White | 2 | 3 | 2 | 2 | 1 | 10 |
| Race — Not Reported | 0 | 0 | 0 | 0 | 2 | 2 |
| Race — Unknown | 0 | 0 | 0 | 0 | 0 | 0 |
| Ethnicity(Participants) | ATSN-101 Cohort 1 | ATSN-101 Cohort 2 | ATSN-101 Cohort 3 | ATSN-101 Cohort 4 (Adult Expansion) | ATSN-101 Cohort 5 (Pediatric Expansion) | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 2 | 2 |
| Not Hispanic or Latino | 3 | 3 | 3 | 3 | 1 | 13 |
| Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown | 0 | 0 | 0 | 0 | 0 | 0 |
| Baseline Height (cm)(cm) | ATSN-101 Cohort 1 | ATSN-101 Cohort 2 | ATSN-101 Cohort 3 | ATSN-101 Cohort 4 (Adult Expansion) | ATSN-101 Cohort 5 (Pediatric Expansion) | Total |
|---|---|---|---|---|---|---|
| Mean | 165.0 ± 11.27 | 174.7 ± 7.57 | 165.7 ± 1.15 | 163.7 ± 8.33 | 158.0 ± 10.15 | 165.4 ± 9.05 |
| Baseline Weight (kg)(kg) | ATSN-101 Cohort 1 | ATSN-101 Cohort 2 | ATSN-101 Cohort 3 | ATSN-101 Cohort 4 (Adult Expansion) | ATSN-101 Cohort 5 (Pediatric Expansion) | Total |
|---|---|---|---|---|---|---|
| Mean | 77.9 ± 26.29 | 69.3 ± 15.61 | 60.5 ± 11.03 | 65.7 ± 18.34 | 54.5 ± 1.46 | 65.6 ± 16.32 |
| Baseline BMI (kg/m^2)(kg/m^2) | ATSN-101 Cohort 1 | ATSN-101 Cohort 2 | ATSN-101 Cohort 3 | ATSN-101 Cohort 4 (Adult Expansion) | ATSN-101 Cohort 5 (Pediatric Expansion) | Total |
|---|---|---|---|---|---|---|
| Mean | 28.0 ± 5.44 | 22.6 ± 3.94 | 22.0 ± 3.70 | 24.4 ± 5.69 | 22.1 ± 3.50 | 23.8 ± 4.51 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/
Ran from Oct 2019 to primary completion in May 2023, 42 months.
Results were first posted in Aug 2026, 3 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Atsena Therapeutics Inc.